teva-deferasirox tablet for suspension
teva canada limited - deferasirox - tablet for suspension - 250mg - deferasirox 250mg - heavy metal antagonists
teva-deferasirox tablet for suspension
teva canada limited - deferasirox - tablet for suspension - 500mg - deferasirox 500mg - heavy metal antagonists
cyramza 10 mgml
eli lilly israel ltd, israel - ramucirumab - concentrate for solution for infusion - ramucirumab 10 mg/ml - ramucirumab - gastric cancercyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.colorectal cancercyramza, in combination with folfiri (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.non-small cell lung cancercyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung adenocarcinoma with activating epidermal growth factor receptor (egfr) mutations.cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.hepatocellular carcinomacyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (afp) of ≥ 400 ng/ml and who have been previously treated with sorafenib.
cyramza
eli lilly nederland b.v. - ramucirumab - stomach neoplasms - antineoplastic agents - gastric cancercyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.colorectal cancercyramza, in combination with folfiri (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.non-small cell lung cancercyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.hepatocellular carcinomacyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (afp) of ≥ 400 ng/ml and who have been previously treated with sorafenib.
cyramza concentrate for solution for infusion 100mg10ml
dksh singapore pte. ltd. - ramucirumab - injection, solution, concentrate - ramucirumab 10mg/ml
cyramza concentrate for solution for infusion 500mg50ml
dksh singapore pte. ltd. - ramucirumab - injection, solution, concentrate - ramucirumab 10mg/ml
folivin 5 mg capsule
vamsler phils. incorporated; distributor: ultramed pharma, inc. - folic acid - capsule - 5 mg
fluvirin 0.5 millilitre
glaxo laboratories limited - 0.5 millilitre
fluvirin 5.0 millilitre
glaxo laboratories limited - 5.0 millilitre
fluvirin 0.5 millilitre
glaxo laboratories limited - 0.5 millilitre